East Florida Eye Institute | Stuart

Research site

About

East Florida Eye Institute is at the forefront of ophthalmic research, contributing to the development of innovative treatments for eye conditions. We are excited to offer our patients the opportunity to participate in groundbreaking studies.

Location

509 SE Riverside Drive, Stuart, Florida, United States of America

Website

https://www.efei.com/research

Site insights

Top conditions

Top treatments

APL-2

Abicipar Pegol

RVL-1201

Bimatoprost

Aflibercept

Bevacizumab

Squalamine Lactate

Ranibizumab

PVP

Timolol Maleate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Joe Boban

Verified by this site

Active trials

5 of 26 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling

Macular Edema Secondary to Retinal Vein Occlusion

Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Drug: Sham

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling

Open-angle Glaucoma

Ocular Hypertension

Other: Sham Administration

Drug: AGN-193408 SR

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol